The etonogestrel contraceptive implant is a type of LARC with proven high efficacy. Yet, similar to all progestin only contraception, abnormal bleeding can become bothersome to the patient- especially in the first 3 to 6 months of use. Ulipristal, a progesterone receptor modulator, has shown promise as a new medical agent to help relieve bothersome bleeding in these patients. In this podcast, we will review the latest data from a randomized controlled trial (Oct 2018) on ulipristal for bleeding control in Nexplanon users.